🇺🇸 FDA
Pipeline program

VK5211

VK5211-201

Phase 2 small_molecule completed

Quick answer

VK5211 for Hip Fractures is a Phase 2 program (small_molecule) at Viking Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Viking Therapeutics
Indication
Hip Fractures
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials